Latest Conference Articles

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Adding ivonescimab to chemotherapy improved PFS for patients with EGFR-mutated non–small cell lung cancer after treatment with a third-generation TKI.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

New AQUILA data show PFS improvement in patients with smoldering multiple myeloma who were treated with subcutaneous daratumumab vs active monitoring.

Mortality, progression, and venous thromboembolism were among outcomes improved for patients with polycythemia vera taking a GLP-1a.

Patients with intermediate- or high-risk MDS experienced a higher modified overall response rate with the venetoclax/azacitidine vs placebo/azacitidine.

Nurses must stay up to date on novel agents and their toxicities to properly monitor for and manage immune effector cell-associated neurotoxicity syndrome.

The role of nurses and APPs is crucial to ensuring patients with cancer can receive newer therapies, shares David A. Braun, MD, PhD.

Nurse practitioner Beth Faiman shares strategies to reduce infection risk in patients receiving bispecific antibodies for multiple myeloma.

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.

Beyond administering CAR T-cell therapy and bispecifics, oncology nurses must apply proactive, supportive care and an understanding of complex treatments.

David A. Braun, MD, PhD, explained that personalized cancer vaccines can be associated with toxicities typical of both vaccines and immunotherapies.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.

While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, shared Wenxin (Vincent) Xu, MD.

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.